Diagnosis and prognosis of brain tumors in clinical trials

Doctoral thesis English OPEN
Gorlia, Thierry;
  • Publisher: Erasmus University Rotterdam
  • Subject: brain tumors | prognostic factors | neurology

textabstractAccording to the Central Brain Registry Of The United States (CBTRUS) statistical report (February 2012) the incidence rate of all primary non malignant and malignant brain and central nervous system tumors is 19.89 cases per 100.000 (11.58 for non-malignant... View more
  • References (13)
    13 references, page 1 of 2

    1. Louis DN, Ohgaki H, Wiestler OD, et al.: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-109, 2007.

    2. Miller CR, Dunham CP, Scheithauer BW, et al.: Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed highgrade gliomas. J Clin Oncol 24:5419-5426, 2006.

    3. Nelson JS, Tsukada Y, Schoenfeld D, et al.: Necrosis as a prognostic criterion in malignant supratentorial, astrocytic gliomas. Cancer 52:550-554, 1983.

    4. Fulling KH, Garcia DM: Anaplastic astrocytoma of the adult cerebrum. Prognostic value of histologic features. Cancer 55:928-931, 1985.

    5. Kouwenhoven MC, Gorlia T, Kros JM, et al.: Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. Neuro Oncol 11:737-746, 2009.

    6. Hegi ME, Janzer RC, Lambiv WL, et al.: Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. Acta Neuropathol 123:841-852, 2012.

    7. Kros JM, Gorlia T, Kouwenhoven MC, et al.: Panel review of anaplastic oligodendroglioma from EORTC trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss and correlations with outcome. J Neuropathol Exp Neurol 66:545-551, 2007.

    8. Gorlia T, van den Bent MJ, Hegi ME, et al.: Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 9:29-38, 2008.

    9. van den Bent MJ, Hartmann C, Preusser M, et al.: Interlaboratory comparison of IDH mutation detection. J Neurooncol, 2013.

    10. Weller M, Stupp R, Reifenberger G, et al.: MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 6:39-51, 2010.

  • Metrics
Share - Bookmark